• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

What’s Nex-T: Innovator Roundtable on T Cell Therapies in Oncology

Thursday, June 06, 2024
Breakout Session
Oncology
24BC
Six CAR-T cell therapies have been approved by the FDA over the last six years to treat various types of blood cancers. While modulating T cells represents a monumental step forward in cancer treatment, challenges remain for successfully treating more patients with this approach. One of the most pressing issues is the high relapse rate, affecting up to 60% of patients previously treated with CAR-T therapies. Beyond efficacy challenges, innovators struggle with limited indications and eligible patients, the high cost of engineered cell therapy solutions, B cell aplasia and manufacturing challenges. In a roundtable style, companies who are tackling some of these challenges will discuss the future of T cell directed approaches in cancer, and how new applications of CAR-T and other methods can successfully treat more patients. This discussion is increasingly important in a global cancer therapeutics market projected to be worth more than $250B by the year 2030.
Moderator
Angus Liu
Senior Writer
Fierce Pharma / Fierce Biotech
Speakers
Keir Loiacono, JD
Chief Executive Officer
BlueSphere Bio
Dan Passeri, JD
Chief Executive Officer
Cue Biopharma
David Fontana, PhD
Chief Operating and Chief Business Officer
Umoja Biopharma
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS